Why is my hematocrit high on testosterone? Erythrocytosis, polycythemia, and the numbers that matter
Dr. Ty Tallman, NMD · Medical Director, Integrative Medical Partners, Mesa AZ · Updated September 13, 2026
Testosterone tells your bone marrow to make more red blood cells. In some men on therapy, the count climbs high enough that the blood gets thicker, and the lab shows it as a high hematocrit or hemoglobin. Doctors call this secondary erythrocytosis. Many people call it polycythemia. It is the most common side effect of testosterone therapy, it depends on the dose and the form of testosterone, and it is reversible. It is not the same as polycythemia vera, which is a bone marrow disease.
I have managed hormone therapy for more than twenty years, and hematocrit is a number I check on every man, at every visit. Here is why it rises, who it happens to, when it matters, how it is managed, and how it differs from the marrow condition people worry about when they search this.
Why testosterone raises red blood cells
Three things happen at once. First, testosterone turns down a liver hormone called hepcidin, by more than half. Hepcidin is the brake on iron absorption. With the brake off, your gut takes in more iron and your body releases stored iron, so the marrow has more raw material for hemoglobin. Second, testosterone resets the thermostat for erythropoietin, or EPO, the kidney hormone that tells the marrow to make red cells. The body keeps making cells past the count where it used to stop. Third, testosterone acts directly on the marrow cells that turn into red cells. The rise is biggest in the first three to six months, then levels off. If therapy stops, the count drifts back to baseline over three to twelve months.
Who is most likely to see it
- Men on injections, especially long-acting ones. Injections produce higher peaks. In one comparison, about 44 percent of men on injections developed erythrocytosis versus about 15 percent on skin gels or patches.
- Higher doses, and dosing schedules with big peaks and deep troughs.
- Older age, higher body weight, and smoking.
- Sleep apnea or lung disease, because low oxygen at night is its own signal to make red cells.
Erythrocytosis is not polycythemia vera
Polycythemia vera is a chronic bone marrow disease, a type of blood cancer, driven by a mutation in a gene called JAK2. The marrow makes too many cells on its own, and it needs a hematologist and long-term treatment. Testosterone-induced erythrocytosis is different: the marrow is healthy and doing what it is told. Two labs tell them apart.
| Lab | Polycythemia vera | Testosterone-induced erythrocytosis |
|---|---|---|
| EPO level | Low | Normal or high |
| JAK2 mutation | Positive | Negative |
| White cells and platelets | Often high too | Normal |
| When testosterone stops | Nothing changes | Count returns to baseline over months |
If a man’s count is much higher than his dose would explain, or his white cells and platelets are also up, I order EPO and JAK2 before I blame the testosterone.
The numbers that guide management
Guidelines use hematocrit, the percent of your blood that is made of red cells. The Endocrine Society and the American Urological Association draw these lines:
- Before starting: a hematocrit already above about 48 to 50 percent is a reason to find out why before beginning testosterone.
- On therapy: hematocrit is checked before the first dose, again at three to six months, then at least yearly. In our office it is checked at every follow-up.
- Above 54 percent: therapy is paused until the count comes back to normal, then restarted at a lower dose. Sleep apnea and lung disease get looked for. A therapeutic blood draw can bring the number down faster.
How it is managed
Erythrocytosis is managed by changing the regimen, not by giving up on treatment. The main levers: lower the dose; split the dose into smaller, more frequent amounts, which flattens the peaks; switch from intramuscular to subcutaneous injections, which produce lower peaks with the same average level; or move to a gel, cream, or patch. Therapeutic phlebotomy, removing about a pint of blood, lowers hematocrit within a day or two. It is a useful adjunct, not a plan by itself. The count rebuilds over the following weeks, and every draw also removes iron, so a man who keeps donating to chase a number can end up iron-depleted with a hematocrit that is still climbing. My page on donating blood explains why “just go donate” is not a strategy.
Does a high hematocrit raise heart attack or clot risk?
Here is where I have to be careful, because the evidence points two ways. The largest randomized trial of testosterone therapy, called TRAVERSE, followed more than 5,000 men at high heart risk for about two years. It found no increase in heart attack, stroke, or cardiovascular death compared with placebo. That is reassuring. But TRAVERSE used a skin gel, the form least likely to raise hematocrit, and it excluded men whose hematocrit was already above 54 percent. It was not built to test what happens when the count runs high. It also saw more blood clots in the lung in the testosterone group, 24 versus 12, a signal that did not reach statistical significance but that I do not ignore.
The observational data are more pointed. In a database of 74 million patients, men whose hematocrit rose to 52 percent or higher on testosterone had more heart events and clots in the first year than matched men whose count stayed normal: about 5.2 percent versus 3.9 percent. Men on testosterone who did not develop erythrocytosis had no extra risk at all. A second analysis found that any rise in hematocrit from baseline tracked with more events at three months and at two years. Outside of testosterone, population studies link a hematocrit above 48 to 49 percent with more heart disease. The likely mechanism is simple physics: thicker blood flows slower and clots more easily.
My read: the exact hematocrit that causes harm has not been pinned down, and clot rates in treated men have been low in most studies. That is not a reason to relax. It is a reason to monitor, keep hematocrit in range, and act early rather than late.
Iron, ferritin, and the other side of this coin
Because testosterone pushes iron into new red cells, men on therapy often see ferritin fall while hematocrit rises. That is expected. The opposite situation, a high ferritin, is a separate question about iron overload, and I cover it on my page on hyperferritinemia and high ferritin. A man who has both hereditary hemochromatosis and low testosterone needs both managed, and the order matters. Where your testosterone itself should sit is on normal testosterone levels in men, and how we monitor therapy is on testosterone therapy in Mesa.
Frequently asked questions
Should I stop testosterone if my hematocrit is high?
Not on your own. Depending on the number, the answer is usually a dose change, a route change, or a short pause with a plan to restart. Stopping abruptly and staying off is rarely the right move. The count comes down either way; the question is how to keep it down while you keep the benefit.
Is a hematocrit of 52 percent dangerous?
It is above the range most labs use for men, and it is the level where observational studies start to see more clots and heart events. It is not an emergency. It is a reason to adjust the regimen now rather than wait for the next annual check.
Do I need to see a hematologist?
If your EPO is low, your JAK2 test is positive, your platelets or white cells are also high, or your count does not respond to regimen changes, yes. Most men on therapy never need one.
Does drinking more water help?
Dehydration can nudge a hematocrit reading up, so drinking water before a lab draw gives a truer number. It does not treat erythrocytosis.
Can this happen with pellets or gels too?
Any form of testosterone can raise hematocrit. Forms with higher peaks carry more risk; steady, lower-peak forms carry less. The monitoring is the same regardless of form.
Measure, don’t guess
If you are on testosterone and no one has checked your hematocrit in the last six months, that is the first thing to fix. If you are thinking about starting, a complete blood count, iron studies, and a conversation about sleep apnea come before the first dose. Bring your labs. We will look at the whole picture, hematocrit, hemoglobin, ferritin, and EPO if needed, and build a regimen that keeps your levels where they help you and your blood where it flows.
Text us at 480-485-2197 to schedule, or call. Quick response, real scheduling, no phone tree.
To Health and Wellness,
Dr. Ty Tallman
This page is educational and is not a substitute for individualized medical advice, diagnosis, or treatment. Decisions about testosterone dosing and hematocrit belong with the physician managing your therapy.
References
International Journal of Impotence Research, 2022 — testosterone therapy and secondary erythrocytosis.
The New England Journal of Medicine, 2023 — cardiovascular safety of testosterone-replacement therapy, the TRAVERSE trial.
The Journal of Urology, 2022 — secondary polycythemia in men receiving testosterone therapy and risk of major adverse cardiovascular events and venous thromboembolism in the first year.
The Journal of Urology, 2024 — rises in hematocrit and risk of major adverse cardiovascular events in men starting testosterone therapy.
The Journal of Urology, 2022 — effect of route of testosterone on changes in hematocrit, network meta-analysis of randomized trials.
The Journal of Urology, 2022 — intramuscular testosterone cypionate versus subcutaneous testosterone enanthate outcomes in hypogonadal men.
The Journal of Clinical Endocrinology and Metabolism, 2018 — Endocrine Society clinical practice guideline on testosterone therapy in men with hypogonadism.
The Journal of Clinical Endocrinology and Metabolism, 2022 — testosterone therapy with subcutaneous injections.
American Urological Association, 2024 — guideline on the evaluation and management of testosterone deficiency.
JAMA, 2025 — diagnosis and treatment of polycythemia vera.
American Journal of Hematology, 2025 — JAK2-unmutated erythrocytosis, update on diagnosis and management.
The New England Journal of Medicine, 2025 — testosterone treatment in middle-aged and older men with hypogonadism.
The New England Journal of Medicine, 2026 — sex hormone influences on venous thrombotic and cardiovascular risk.
Mayo Clinic Proceedings, 2024 — Androgen Society position paper on cardiovascular risk with testosterone therapy.
Best Practice & Research Clinical Endocrinology & Metabolism, 2022 — haematological actions of androgens.